{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Azenta, Inc. Hits Day High with 16.3% Surge in Stock Price
Azenta, Inc. experienced a notable stock surge today, gaining 16.3% and reaching an intraday high. Over the past week, it has outperformed the S&P 500, despite a longer-term decline. The company reported strong operating cash flow, but faces challenges with negative operating profits and declining net sales.
Azenta, Inc. Opens with 13.33% Gain, Outperforming S&P 500's 0.98% Rise
Azenta, Inc. experienced a significant one-day stock increase, contrasting with the S&P 500's modest rise. While the company has shown resilience over the past month, it faces long-term challenges, including declining net sales and operating profit. Institutional holdings remain strong, indicating investor confidence amid ongoing performance scrutiny.
Azenta, Inc. Experiences Revision in Its Stock Evaluation Amid Challenging Market Conditions
Azenta, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, is facing financial challenges, reflected in its negative P/E ratio and low returns on capital. Compared to peers, its valuation metrics suggest a precarious position, with significant stock volatility and a negative year-to-date return amid a stronger market backdrop.
Is Azenta, Inc. overvalued or undervalued?
As of November 21, 2025, Azenta, Inc. has shifted from a risky to an attractive valuation grade, appearing undervalued with a Price to Book Value of 1.00 and an EV to Sales ratio of 2.17, despite operational challenges reflected in its high EV to EBITDA ratio of 38.38 compared to peers and negative return metrics.
Is Azenta, Inc. overvalued or undervalued?
As of November 21, 2025, Azenta, Inc. has an attractive valuation grade despite being undervalued with a Price to Book Value of 1.00 and an EV to Sales ratio of 2.17, but it has underperformed the S&P 500 with a year-to-date return of -30.22% and a 5-year return of -48.06%.
Azenta, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Azenta, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced notable stock fluctuations, with a recent closing price of $29.55. Despite some weekly bullish indicators, the overall performance has lagged behind the S&P 500, reflecting challenges in the competitive market landscape.
Azenta, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility
Azenta, Inc., a small-cap company in the Pharmaceuticals and Biotechnology sector, has experienced notable stock fluctuations, with a recent closing price of $30.52. The stock has underperformed compared to the S&P 500, declining significantly over the past year and year-to-date, reflecting challenges in the competitive market.
Is Azenta, Inc. technically bullish or bearish?
As of October 10, 2025, Azenta, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 significantly with a year-to-date return of -40.38% compared to the S&P's 11.41%.
Is Azenta, Inc. technically bullish or bearish?
As of September 12, 2025, Azenta, Inc. has shifted to a bearish trend with mixed technical signals, underperforming the S&P 500 with a year-to-date return of -37.88%.
Is Azenta, Inc. overvalued or undervalued?
As of August 9, 2022, Azenta, Inc. is considered overvalued and risky due to its negative P/E ratio, poor return metrics, and disappointing stock performance, with key ratios indicating it trades at a premium compared to peers like Encompass Health Corp. and The Ensign Group, Inc.
Azenta, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
Azenta, Inc., a small-cap company in the Pharmaceuticals and Biotechnology sector, has recently adjusted its technical trends amid ongoing market challenges. The stock shows a year-to-date return of -40.12%, significantly underperforming the S&P 500. Mixed technical indicators reflect the volatility in Azenta's performance.
Is Azenta, Inc. overvalued or undervalued?
As of August 9, 2022, Azenta, Inc. is considered overvalued and risky, with key financial ratios indicating poor performance compared to peers and a year-to-date stock return of -41.74%, significantly underperforming the S&P 500's 2.44%.
Is Azenta, Inc. technically bullish or bearish?
As of June 3, 2025, Azenta, Inc. has a mildly bearish trend, indicated by mixed signals from MACD, Bollinger Bands, moving averages, and Dow Theory across different timeframes.
Who are in the management team of Azenta, Inc.?
As of March 2022, the management team of Azenta, Inc. includes Dr. Joseph Martin (Independent Chairman), Dr. Stephen Schwartz (President and CEO), and five Independent Directors: Ms. Robyn Davis, Ms. Erica McLaughlin, Prof. Dr. Krishna Palepu, and Mr. Kirk Pond.
What does Azenta, Inc. do?
Azenta, Inc. provides automation solutions for the Pharmaceuticals & Biotechnology industry, with recent net sales of $143 million and a net loss of $18 million. The company has a market cap of $1.74 billion and does not pay dividends.
How big is Azenta, Inc.?
As of Jun 18, Azenta, Inc. has a market capitalization of 1,736.38 million, with net sales of 633.80 million and a net profit of -39.16 million over the latest four quarters. The company reported shareholder's funds of 1,768.97 million and total assets of 2,100.04 million as of Sep 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
